/C O R R E C T I O N -- Heng Ren Partners/
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) will release financial results for the six months ended June 30, 2025, after U.S. markets close on Wednesday, August 13, 2025.
The company will host a conference call to present results and business highlights on Thursday, August 14, 2025 at 8:00 am EDT (12:00 noon GMT, 14:00 CET). Live audio will be webcast on Alvotech's investor portal and the webcast will be archived for replay for 90 days. Access details and phone sign-in instructions are posted at https://investors.alvotech.com/events/event-details/q2-2025-earnings.
Positive
- None.
Negative
- None.
News Market Reaction 4 Alerts
On the day this news was published, ALVO gained 1.82%, reflecting a mild positive market reaction. Argus tracked a trough of -6.2% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $31M to the company's valuation, bringing the market cap to $1.75B at that time.
Data tracked by StockTitan Argus on the day of publication.
REYKJAVIK, Iceland, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first half of the year ended June 30, 2025, after U.S. markets close on Wednesday, August 13, 2025. Alvotech will also conduct a conference call to present the financial results and recent business highlights on Thursday, August 14, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET). Live audio of the conference call will be webcast and available on Alvotech’s investor portal.
Information on how to access the webcast or participate by conference call is posted on Alvotech’s investor portal https://investors.alvotech.com. Specifically, links to access the webcast and instructions to sign in by phone can be found at https://investors.alvotech.com/events/event-details/q2-2025-earnings. The webcast will also be archived and available for replay for 90 days after the event.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.
FAQ
When will Alvotech (ALVO) release its H1 2025 financial results?
What time is the Alvotech (ALVO) earnings conference call for H1 2025?
How can investors access the Alvotech (ALVO) H1 2025 webcast?
Will the Alvotech (ALVO) earnings webcast be available after the live call?
Where are phone sign-in instructions for the Alvotech (ALVO) conference call?
